Table 3.
Cox regression analysis of OS in patients with AGC treated with PD-1 inhibitors after propensity score matching
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR1 (95% CI)1 | P value | HR1 (95% CI)1 | P value | |
| Gender | ||||
| Male | 1 (Reference) | |||
| Female | 1.040 (0.484-2.235) | 0.919 | - | - |
| Age | ||||
| ≤65 | 1 (Reference) | |||
| >65 | 0.689 (0.370-1.285) | 0.239 | - | - |
| ECOG PS | ||||
| ≤1 | 1 (Reference) | |||
| ≥2 | 2.092 (0.646-6.772) | 0.208 | - | - |
| Peritoneum metastasis | ||||
| Negative | 1 (Reference) | |||
| Positive | 2.180 (1.176-4.043) | 0.011 | 1.484 (0.724-3.043) | 0.281 |
| Liver metastasis | ||||
| Negative | 1 (Reference) | |||
| Positive | 0.811 (0.461-1.427) | 0.468 | - | - |
| Lung metastasis | ||||
| Negative | 1 (Reference) | |||
| Positive | 0.897 (0.420-1.918) | 0.779 | - | - |
| Lymph node metastasis | ||||
| Negative | 1 (Reference) | |||
| Positive | 1.273 (0.724-2.238) | 0.402 | - | - |
| Metastasis sites | ||||
| ≤2 | 1 (Reference) | |||
| ≥3 | 2.863 (1.549-5.293) | <0.001 | 2.978 (1.587-5.587) | 0.001 |
| Treatment lines | ||||
| ≤2 | 1 (Reference) | |||
| ≥3 | 1.691 (0.881-3.247) | 0.110 | 2.010 (1.019-3.963) | 0.044 |
| Treatment types | 0.319 | |||
| Chemotherapy+targeted therapy | 1 (Reference) | |||
| Chemotherapy | 0.858 (0.446-1.647) | 0.644 | - | - |
| Others | 1.689 (0.640-4.459) | 0.290 | - | - |
| HSP90α | ||||
| ≤82 | 1 (Reference) | |||
| >82 | 1.704 (0.967-3.004) | 0.062 | 1.977 (1.099-3.559) | 0.023 |
| HER-2 | ||||
| Negative/Unknown | 1 (Reference) | |||
| Positive | 0.501 (0.180-1.394) | 0.177 | 0.565 (0.201-1.590) | 0.280 |
| NLR | ||||
| ≤3 | 1 (Reference) | |||
| >3 | 1.762 (1.000-3.105) | 0.047 | 1.888 (1.061-3.358) | 0.031 |
1HR = Hazard Ratio, CI = Confidence Interval